Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Phibro Animal Health (PAHC) Net Income towards Common Stockholders (2016 - 2026)

Phibro Animal Health has reported Net Income towards Common Stockholders over the past 14 years, most recently at $27.5 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 762.14% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $92.1 million, up 1157.72%, while the annual FY2025 figure was $48.3 million, 603.85% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $27.5 million at Phibro Animal Health, up from $26.5 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $27.5 million in Q4 2025 and troughed at -$11.2 million in Q2 2024.
  • A 5-year average of $8.6 million and a median of $7.1 million in 2022 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 307.86% in 2023 and later soared 762.14% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $17.5 million in 2021, then tumbled by 58.72% to $7.2 million in 2022, then crashed by 82.33% to $1.3 million in 2023, then soared by 150.0% to $3.2 million in 2024, then surged by 762.14% to $27.5 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for PAHC at $27.5 million in Q4 2025, $26.5 million in Q3 2025, and $17.2 million in Q2 2025.